Tower Research Capital (TRC)’s Ambrx Biopharma Inc AMAM Stock Holding History

Tower Research Capital (TRC)’s Portfolio AMAM Stock Details AMAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,614	Closed	-$79.9K	–	6285
2023 Q4	$79.9K	Buy	5,614 +5,379	+2,289%	+$61.1K	﹤0.01%	2808
2023 Q3	$2.7K	Buy	+235	New	+$3.2K	﹤0.01%	5114
2023 Q2	–	Sell	-20,440	Closed	-$182K	–	6473
2023 Q1	$182K	Buy	20,440 +20,437	+681,233%	+$103K	0.01%	1421
2022 Q4	$0	Sell	3 -39	-93%	-$45	﹤0.01%	6571
2022 Q3	$0	Buy	+42	New	+$86	﹤0.01%	6667

Tower Research Capital (TRC)'s AMAM Position: Q1 2024 in Review

Tower Research Capital (TRC) sold out of Ambrx Biopharma Inc (AMAM) in Q1 2024, closing a stake of 5,614 shares — an estimated $79.9K sold.

Tower Research Capital (TRC) first reported a position in AMAM in Q3 2022 and held it in 5 quarters. The position peaked at $182K in Q1 2023. 0 funds tracked by Wall St. Rank hold AMAM as of Q1 2024.

Tower Research Capital (TRC) reported no remaining Ambrx Biopharma Inc position as of Q1 2024 after selling out during the quarter.
Tower Research Capital (TRC) sold 5,614 Ambrx Biopharma Inc shares in Q1 2024, an estimated $79.9K.
Tower Research Capital (TRC) first reported a position in Ambrx Biopharma Inc in Q3 2022 and held it in 5 quarters.
Tower Research Capital (TRC)'s Ambrx Biopharma Inc position peaked at $182K in Q1 2023.
0 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2024, filed 15 May 2024.